AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of CancerStephen R. Wedge, Donald Ogilvie|Cancer Research|2005Cited by 710
Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascadeAmanda J. Watson, Donald Ogilvie|F1000Research|2016Cited by 6
Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascadeAmanda J. Watson, Donald Ogilvie|F1000Research|2016Cited by 6